Abstracts Archive - Page 300 of 2425 - ACR Meeting Abstracts

Abstract Number: 2042 • ACR Convergence 2023
Intraocular Cytokine Profiling of Autoimmune Uveitis
Maryrose Hahn¹, Madison Mangin², Marc Todd¹, Pui Lee¹, Mindy Lo¹, Bharti Gangwani³, Ankoor Shah³, Amanda Colombo⁴, Jessica Scott⁴, Stephen Anesi⁴, C. Stephen Foster⁴, Peter Chang⁴, Peter Nigrovic² and Margaret Chang², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Department of Ophthalmology, Boston Children's Hospital, Boston, MA, ⁴Massachusetts Eye Research and Surgery Institution, Waltham, MA
Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies.…
Abstract Number: 2048 • ACR Convergence 2023
Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)
Farzana Nuruzzaman¹, T. Shawn Sato², Andrew Carbert³, Joel Paschke³, Lauren Potts⁴, Meinrad Beer⁵, Mingqian Huang⁶, Ramesh Iyer⁷, Johanna Monsalve⁸, Anh-Vo Ngo⁷, Jennifer Stimec⁹, Mahesh Thapa⁷, Xiaoyue Zhang¹⁰, Walter P. Maksymowych¹¹, Polly Ferguson¹² and Yongdong (Dan) Zhao¹³, ¹Stony Brook Children's Hospital, Stony Brook, NY, ²University of Iowa, Iowa City, IA, ³CARE Arthritis, Edmonton, AB, Canada, ⁴Illustrator/Patient Research Partner, Long Beach, CA, ⁵University Hospital, Ulm Germany, Ulm, Germany, ⁶Mount Sinai Hospital, New York, NY, ⁷University of Washington, Seattle, WA, ⁸SUNY-Stony Brook Hospital, Stonybrook, NY, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Biostatistical Consulting Core - Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, ¹¹University of Alberta, Edmonton, AB, Canada, ¹²University of Iowa Carver College of Medicine, Iowa City, IA, ¹³University of Washington, Redmond, WA
Background/Purpose: The ChRonic nonbacterial Osteomyelitis Magnetic Resonance Imaging Scoring (CROMRIS) tool was developed but it was not digitized yet. Our objectives are: 1) to adapt…
Abstract Number: 2045 • ACR Convergence 2023
Treatment Response in a Cohort of Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)
Ilaria Maccora¹, Arjun Sood², Grant Schulert³, Alexandra Duell³, Preston Land⁴, Cameron C Sapp², Jennifer Huggins³, Tiffany Nguyen², Megan Quilan-Waters³, Sumit Sharma⁵, Sunil Srivastava² and Sheila Angeles-Han⁶, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Cincinnati Eye Institute, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Medical Center, Cincinnati, OH, ⁵Cleveland Clinic, Cleveland, OH, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric uveitis often requires systemic immunomodulatory therapy (IMT) to prevent sight-threatening complications. Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a rare autoimmune condition caused…
Abstract Number: 2039 • ACR Convergence 2023
Clinical, Immunologic, and Genetic Characteristics in Patients with Syndrome of Undifferentiated Recurrent Fevers (SURF)
Marci Macaraeg, Michael Matt, Elizabeth Handorf, Elizabeth Baker and Grant Schulert, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Unexplained recurrent fevers are a common presentation to pediatric rheumatology and a significant burden to affected families due to missed daycare or school days…
Abstract Number: 2054 • ACR Convergence 2023
Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience
Ilaria Maccora¹, Catherine Guly², Lavinia Sanfilippo³, sara Soldovieri⁴, Cinzia De Libero⁵, Athimalaipet V Ramanan⁶ and Gabriele Simonini⁷, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Ophthalmology Unit, Bristol Eye Hospital, Bristol, United Kingdom, ³Meyer Children's Hospital IRCCC, Florence, Italy, ⁴Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, ⁶Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom, ⁷Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: Childhood Chronic Idiopathic Uveitis (cCIU) is a severe ocular condition that accounts for the 40% of all uveitis in children. Its timely and proper…
Abstract Number: 2037 • ACR Convergence 2023
Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology
COMFORT ANIM-KORANTENG¹, YONG EUN², Okeoghene Akpoigbe² and AMANDA SAMMUT², ¹Harlem Hospital Center, New York, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Many studies have shown that rheumatologic conditions are associated with a higher risk of depression. The two most common methods to detect depression in…
Abstract Number: 1220 • ACR Convergence 2023
Sjögren’s Patients’ Experiences and Content Validity of the Dry Eye Disease Symptom Questionnaire (DED-SQ)
Denise Kruzikas¹, Ann Eldred², Shelly Kafka³, Janet Church⁴, Katherine Hammitt⁴, Patricia Koochaki⁵ and Christina O'Donnell⁶, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Inc., Lake Bluff, IL, ³AbbVie, Inc., Norristown, PA, ⁴Sjögren’s Foundation, Reston, VA, ⁵ICON Clinical Research LLC, Raleigh, NC, ⁶ICON plc, Raleigh, NC
Background/Purpose: Dry eye is one of the most important and prevalent symptoms experienced by patients with Sjögren's Disease (SJD). The DED-SQ is a 12-item patient…
Abstract Number: 1784 • ACR Convergence 2023
Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model
Raminderjit Kaur¹, M. Elaine Husni², Unnikrishnan Chandrasekharan³ and Roberta Brambilla⁴, ¹Cleveland Clinic, Cleveland,, OH, ²Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH, ⁴University of Miami Miller School of Medicine, Miami,, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive autoimmune condition that affects both the skin and joints. It is characterized by increased levels of the…
Abstract Number: 1271 • ACR Convergence 2023
Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)
Bong-Ki Hong¹, Sungyong You², Naeun Lee¹, Jung Gon Kim³, Kijun Lee⁴, Ji Hyeon Ju⁵, Wan-Uk Kim¹ and Ho-Youn Kim⁶, ¹The Catholic University of Korea, Seoul, South Korea, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Inje University Ilsan Paik Hospital, Goyang, South Korea, ⁴YiPSCELL, Secho, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶HoYoun Kim's Clinic for Arthritis Rheumatism, Seoul, South Korea
Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…
Abstract Number: 2047 • ACR Convergence 2023
Safety of Baricitinib for COVID-19 Related Hyperinflammation in Pediatric Patients: A Large Tertiary Care Center Experience
Meredith Rae¹, Jessica Nguyen², Marietta DeGuzman³, Catherine Foster¹, Flor Munoz¹ and Eyal Muscal⁴, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Manvel, TX, ³Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ⁴Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: A small proportion of children with acute COVID-19 experienced life-threatening hyperinflammation. It has been proposed that an innate immune recognition of viral RNA triggers…
Abstract Number: 1230 • ACR Convergence 2023
Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive
Nicholas McClellan, Sarah Vandenbergen, Sophia Matossian, J. Michelle Kahlenberg and Jessica Turnier, University of Michigan, Ann Arbor, MI
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by multiorgan vasculopathy, and degree of vasculopathy can indicate more severe disease. Nailfold capillaroscopy is a non-invasive method to…
Abstract Number: 1281 • ACR Convergence 2023
Risk of Cancer in Patients with Rheumatoid Arthritis Under Tocilizumab: Data from the French National Registry REGATE
JACQUES MOREL¹, Amélie Wetzman², Daniel Wendling³, Martin Soubrier⁴, Olivier Roth⁵, Jacques-Eric Gottenberg⁶, Philippe Goupille⁷, Xavier Mariette⁸ and Cedric Lukas⁹, ¹Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ²CHU and University of Montpellier, Narbonne, France, ³Besançon University Hospital, Besançon, France, ⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ⁵Saint Joseph Hospital, Marseille, France, ⁶Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ⁷CHU and University of Tours, Tours, France, ⁸Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁹CHU Montpellier, Montpellier, France
Background/Purpose: Our study aimed to estimate the incidence and risk factors of cancer among rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) and followed for…
Abstract Number: 1793 • ACR Convergence 2023
Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis
Amy Cameron¹, Rabina Giri², Jakob Begun², Timothy Wells¹, Ranjeny Thomas³ and Anne-Sophie Bergot¹, ¹Frazer Institute, The University of Queensland, Woolloongabba, Australia, ²Mater Research Institute-UQ, Woolloongabba, Australia, ³Frazer Institute, The University of Queensland, Brisbane, Australia
Background/Purpose: The loss of intestinal barrier integrity is a key contributor to gut inflammation, however the mechanism behind this dysregulation is not well understood. The…
Abstract Number: 2049 • ACR Convergence 2023
Vaccination Coverage and Caregiver Perspectives for Children with Rheumatic Diseases Compared to Healthy Controls
Shine Vazhappilly¹, Racheal Githumbi², Nicole Johnson², Otto G Vanderkooi² and Heinrike Schmeling², ¹Saba University, Blue Ash, OH, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: Children with rheumatic diseases (RD) have an increased incidence of infections and their complications, both from underlying disease activity and immunosuppressive treatments. Vaccines have…
Abstract Number: 1804 • ACR Convergence 2023
Plant-based Diet Quality and the Risk of Gout: Results from Two Prospective Cohort Studies of US Men and Women
Sharan Rai¹, Frank Hu¹, Molin Wang¹, Hyon K. Choi² and Qi Sun¹, ¹Harvard T.H. Chan School of Public Health, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Plant-based diets are growing in popularity due to their health benefits for selected cardiometabolic diseases as well as favorable environmental impact. However, the limited…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].